tiprankstipranks
Trending News
More News >
Medtronic (MDT)
NYSE:MDT
US Market

Medtronic (MDT) Earnings Dates, Call Summary & Reports

Compare
6,083 Followers

Earnings Data

Report Date
Aug 19, 2025
TBA Not Confirmed
Period Ending
2026 (Q1)
Consensus EPS Forecast
1.23
Last Year’s EPS
1.23
Same Quarter Last Year
Moderate Buy
Based on 20 Analysts Ratings

Earnings Call Summary

Earnings Call Date:May 21, 2025
|
% Change Since: -0.96%
|
Next Earnings Date:Aug 19, 2025
Earnings Call Sentiment|Positive
The earnings call presented a strong performance with positive revenue growth, especially in Cardiovascular and Neuromodulation segments. The decision to spin off the Diabetes business is seen as a strategic move to focus on higher-margin growth areas. However, concerns about tariff impacts and currency headwinds were noted.
Company Guidance
During Medtronic's fiscal year 2025 fourth-quarter earnings call, the company reported a strong 5.4% organic revenue growth, with significant contributions from its Cardiovascular portfolio, which grew by 8%, and double-digit growth in Neuromodulation and Diabetes. The company achieved a high single-digit operating profit and low double-digit EPS growth, with EPS increasing 11% to $1.62 for the quarter. Medtronic announced its plan to separate the Diabetes business into a standalone public company via a capital market separation, aiming for a tax-free impact on shareholders and anticipating improvements in gross and operating margins by 50 and 100 basis points, respectively. For fiscal year 2026, Medtronic expects organic revenue growth of approximately 5% and EPS growth of about 4%, excluding tariffs. The company also highlighted its ongoing strategic focus on high-margin growth markets and new innovations, such as its Cardiac Ablation Solutions, which grew nearly 30%, and plans for the US launch of its Hugo robot and Symplicity hypertension procedure.
Strong Revenue Growth
The company reported a 5.4% organic revenue growth in Q4, with notable acceleration in Cardiovascular (8%), Neuromodulation, and Diabetes segments.
Cardiac Ablation Solutions Surge
Cardiac Ablation Solutions grew nearly 30%, driven by high demand for Affera PFA products and the Sphere-9 focal catheter.
Neuromodulation Leads Market
Neuromodulation grew 10%, with a 12% increase in Pain Stim and 15% growth in the US, maintaining the number one global position in SCS.
Diabetes Segment Growth
The Diabetes segment achieved 12% growth, marking the sixth consecutive quarter of double-digit growth, with strong contributions from the MiniMed 780G and Simplera Sync sensor.
Significant Operational Leverage
The company achieved high single-digit operating profit and low double-digit EPS growth, with Q4 EPS growth of 11%.
Portfolio Milestones
Two businesses, CAS and ENT, reached $1 billion in annual revenue, joining ten other businesses in this category.
Separation of Diabetes Business
The decision to separate the Diabetes business into a standalone public company is seen as a strategic move for focused growth and investment.

Medtronic (MDT) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

MDT Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Slides
Play Transcript
Aug 19, 2025
2026 (Q1)
1.23 / -
1.23
May 21, 2025
2025 (Q4)
1.58 / 1.62
1.4610.96% (+0.16)
Feb 18, 2025
2025 (Q3)
1.36 / 1.39
1.36.92% (+0.09)
Nov 19, 2024
2025 (Q2)
1.25 / 1.26
1.250.80% (+0.01)
Aug 20, 2024
2025 (Q1)
1.20 / 1.23
1.22.50% (+0.03)
May 23, 2024
2024 (Q4)
1.45 / 1.46
1.57-7.01% (-0.11)
Feb 20, 2024
2024 (Q3)
1.26 / 1.30
1.30.00% (0.00)
Nov 21, 2023
2024 (Q2)
1.18 / 1.25
1.3-3.85% (-0.05)
Aug 22, 2023
2024 (Q1)
1.11 / 1.20
1.136.19% (+0.07)
May 25, 2023
2023 (Q4)
1.55 / 1.57
1.523.29% (+0.05)
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed

MDT Earnings-Related Price Changes

Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
May 21, 2025
$86.37$84.41-2.27%
Feb 18, 2025
$92.08$85.39-7.27%
Nov 19, 2024
$86.16$83.61-2.96%
Aug 20, 2024
$82.78$83.32+0.65%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Medtronic (MDT) report earnings?
Medtronic (MDT) is schdueled to report earning on Aug 19, 2025, TBA Not Confirmed.
    What is Medtronic (MDT) earnings time?
    Medtronic (MDT) earnings time is at Aug 19, 2025, TBA Not Confirmed.
      Where can I see when companies are reporting earnings?
      You can see which companies are reporting today on our designated earnings calendar.
        What companies are reporting earnings today?
        You can see a list of the companies which are reporting today on TipRanks earnings calendar.
          What is MDT EPS forecast?
          MDT EPS forecast for the fiscal quarter 2026 (Q1) is 1.23.

            Medtronic (MDT) Earnings News

            MDT Earnings: Medtronic Stock Slips Despite Earnings Beat
            Premium
            Market News
            MDT Earnings: Medtronic Stock Slips Despite Earnings Beat
            15d ago
            MDT Earnings: Medtronic Diabetes and Heart Devices Drive Beat
            Premium
            Market News
            MDT Earnings: Medtronic Diabetes and Heart Devices Drive Beat
            4M ago
            MDT Earnings: Medtronic Beats Q2 Expectations, Boosts FY25 Guidance
            Premium
            Market News
            MDT Earnings: Medtronic Beats Q2 Expectations, Boosts FY25 Guidance
            7M ago
            MDT Earnings: Medtronic Boosts FY25 Outlook on Strong Q1 Results
            Premium
            Market News
            MDT Earnings: Medtronic Boosts FY25 Outlook on Strong Q1 Results
            10M ago
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis